TNF Pharmaceuticals, Inc. (NASDAQ:TNFA – Get Free Report)’s stock price was up 1.9% during mid-day trading on Tuesday . The stock traded as high as $3.90 and last traded at $3.78. Approximately 268,258 shares traded hands during trading, a decline of 99% from the average daily volume of 32,220,806 shares. The stock had previously closed at $3.71.
TNF Pharmaceuticals Stock Performance
The stock has a fifty day moving average of $3.85 and a 200-day moving average of $4.13. The company has a market cap of $6.98 million, a PE ratio of -0.02 and a beta of 2.04.
About TNF Pharmaceuticals
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.
Recommended Stories
- Five stocks we like better than TNF Pharmaceuticals
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
